Of chief interest among the compounds tested for anticancer activity in the earlier seriesJ3 and so far in the present one, is 6-chloro-2-(2-quinolyl) chromone (XV). This displayed borderline, though significant, activity against Sarcoma 180 in all trials. KO comparable degree of activity was shown by the other 2-(2-quinolyl) chromones (XI11 and XIV) and this finding tempted us to correlate the activity of the compound with the presence of the ...
